ABSTRACT
ABSTRACT: Sodium-glucose cotransporter-2 (SGLT2) inhibitors can decrease risk for heart failure in patients with type 2 diabetes and can decrease risk of major cardiovascular events in patients with heart failure (HF) and diabetes. Specific SGLT2 inhibitors can also decrease major cardiovascular events in patients with HF only.
Subject(s)
Heart Failure/drug therapy , Sodium-Glucose Transporter 2 Inhibitors/therapeutic use , Stroke Volume/drug effects , Clinical Trials as Topic , Heart Failure/classification , Heart Failure/physiopathology , Humans , Referral and Consultation , Sodium-Glucose Transporter 2 Inhibitors/adverse effects , Sodium-Glucose Transporter 2 Inhibitors/pharmacology , Stroke Volume/physiology , Treatment OutcomeABSTRACT
Coronary artery disease is the leading cause of death in both men and women in the United States. Annually, 790,000 Americans will experience a myocardial infarction. Early recognition and appropriate management of myocardial infarction are imperative to improving patient outcomes. This article discusses the pathophysiology, presentation, and diagnosis and management of both ST-elevation myocardial infarction (STEMI) and non-STEMI.
